SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol

Abstract Background Glioblastoma is the most aggressive primary brain tumour in adults with a dismal prognosis and median overall survival of 12–14 months despite standard therapy. Novel discoveries in Cancer Neuroscience have revealed excitatory neuron-to-tumour synapses that drive glioma prolifera...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Jens Toft Eschen, Line Louise Jensen, David Hausmann, Allice Nyborg Rosenkrans Lind, Slavka Lukacova, Joachim Weischenfeldt, Ulrik Lassen, Manfred Westphal, Frank Winkler, Ulf Simonsen, Anders Rosendal Korshoej
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2026-04-01
Rangatū:	BMC Cancer
Ngā marau:	Glioblastoma Cancer neuroscience; window-of-opportunity trial Phase 1 Senicapoc Perampanel Pacemaker cells
Urunga tuihono:	https://doi.org/10.1186/s12885-026-15784-y
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!